Clinical trial registry record

Phase 1 Study of CM082 in Patients With wAMD

A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Suspended. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Suspended.
Evidence
Registered phase 1 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated January 13, 2020.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT02452385
Last registry update
January 13, 2020
Status
Suspended
Phase
Phase 1
Sponsor
AnewPharma
Enrollment
56
Countries
China
Match confidence
60%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Suspended. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 1
Study design
NA · SINGLE GROUP · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
56
Population
ALL · 50 Years
Duration
2015-03-01 to 2020-06-01
Intervention
CM082 tablet
Comparator
Not reported
Outcomes measured
Number of Participants with Adverse Events as a Measure of Safety and Tolerability — six months; Area under the plasma concentration versus time curve (AUC) of CM082 — four weeks; Change in best corrected visual acuity (BCVA) (in number of letters) — six months; Change in Central Retinal Thickness — six months
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 1A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 60% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 60%Source terminology contains a controlled topic term. Source terminology supplies ageing or longevity context.

Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.

vision aging
Read the original source →Export JSON